HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

NCT02461121 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

GENETIC: HLA mismatched stem cell
GENETIC: HLA matched stem cell
DRUG: cyclosporine A
DRUG: Mycophenolate mofetil
DRUG: Ara-C
DRUG: fludarabine
DRUG: anti-lymphocyte globulin
DRUG: cyclophosphamide

Sponsor

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences